Dyne Therapeutics
Dyne Therapeutics is developing therapeutics targeting muscle and the central nervous system for genetically driven neuromuscular diseases, with ongoing programs in diseases like DMD and DM1. The company is focused on delivering transformative medicines and pioneering clinical programs.
Headquarters
Waltham, Massachusetts, United States
Company Size
51-200 employees
Founded
2018
Dyne Therapeutics is a biotechnology company developing nucleic acid–based therapies for genetically driven neuromuscular diseases. Leveraging its proprietary FORCE™ platform, Dyne aims to address the root cause of disease and deliver functional improvement for people living with conditions such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). The company advances a pipeline of therapeutics from discovery through clinical development with the mission of transforming the lives of patients with rare neuromuscular diseases.
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case (NASDAQ:DYN)
2 days ago
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
3 days ago
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8%
22 hours ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Dyne Therapeutics.
111% above the average for this role
150-patient Dyne trial focuses on myotonic dystrophy daily function
3 days ago
Associate Director, Drug Substance Development & Manufacturing
Entrada Therapeutics
Scientist, Chemistry
Octant Bio
Associate Director/Director, Regulatory Affairs-CMC
nChroma Bio
Sr. Principal Scientist - Translational Muscle Biology
City of Pierre, South Dakota
Sr. Principal Scientist - Translational Muscle Biology
City of Winnipeg
Executive Director of Clinical Development (Rare Disease)
Recursion